Tags

Type your tag names separated by a space and hit enter

[Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Ai Zheng 2005; 24(12):1493-7AZ

Abstract

BACKGROUND & OBJECTIVE

Nasal-type NK/T-cell non-Hodgkin's lymphoma (NHL) is a unique subtype with the manifestation of local necrosis, infection and fever. The efficacy of chemotherapy alone is unsatisfactory; while radiochemotherapy plays some roles in the management of NK/T-cell lymphoma (NK/TCL). This study was to summarize the clinical characteristics, treatment outcome and prognosis of NK/TCL patients.

METHODS

Records of 93 patients with NK/TCL from Jan. 1997 to Jun. 2004 were analyzed retrospectively. All the patients were classified according to WHO classification system.

RESULTS

Of the 93 patients, 75 (80.6%) were in stage I-II, and 18 (19.4%) were in stage III-IV. The most common symptoms were nasal obstruction, rhinorrhea, and epistaxis. The disease course was 1-24 months with a median of 6.5 months. Of the 93 patients, 15 (16.1%) presented perforation of hard palate and/or nasal septum, 35 (37.6%) presented B symptoms; 35 (37.6%) were treated with chemotherapy alone, 2 (2.2%) were treated with radiotherapy alone, 54 (58.0%) were treated with radiochemotherapy, and 2 (2.2%) received no treatment. The first-line chemotherapy regimens were mainly CHOP and EPOCH. The overall response rate (RR) was 84.4% (76/90) with complete remission (CR) rate of 64.4% (58/90). The response rate of chemotherapy alone group was 67.6% (23/34) with CR rate of 41.2% (14/34). The response rate of combined modality group was 94.4% (51/54) with CR rate of 83.3% (45/54). The 2 patients who received no treatment died within 6 months. The major toxicity of chemotherapy was myelosuppression. The prevalence of grade III-IV neutropenia, thrombocytopenia, and anemia were 37.7%, 13.7%, and 10.7%. The major toxicities of radiotherapy were grade I-II mucosa lesion and myelosuppression. Other toxicities were mild. The mortality was 66.7% (62/93). The 1-, 3-, and 5-year overall survival (OS) rates were 63.4%, 43.1%, and 17.6%, respectively. Multivariate analysis showed that perforation of hard palate and/or nasal septum, B symptoms and therapeutic modality were independent prognostic factors of NK/TCL (P=0.035, P<0.001, and P=0.004).

CONCLUSIONS

NK/TCL has low chemotherapy sensitivity. Although combined chemoradiotherapy yield better outcome, the long-term survival was still poor. Investigation of optional treatment is needed.

Authors+Show Affiliations

State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

16351799

Citation

Pan, Zhan-He, et al. "[Prognostic Analysis of Patients With Nasal-type NK/T-cell non-Hodgkin's Lymphoma--a Report of 93 Cases]." Ai Zheng = Aizheng = Chinese Journal of Cancer, vol. 24, no. 12, 2005, pp. 1493-7.
Pan ZH, Huang HQ, Lin XB, et al. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng. 2005;24(12):1493-7.
Pan, Z. H., Huang, H. Q., Lin, X. B., Xia, Y. F., Xia, Z. J., Peng, Y. L., ... Guan, Z. Z. (2005). [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng = Aizheng = Chinese Journal of Cancer, 24(12), pp. 1493-7.
Pan ZH, et al. [Prognostic Analysis of Patients With Nasal-type NK/T-cell non-Hodgkin's Lymphoma--a Report of 93 Cases]. Ai Zheng. 2005;24(12):1493-7. PubMed PMID: 16351799.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. AU - Pan,Zhan-He, AU - Huang,Hui-Qiang, AU - Lin,Xu-Bin, AU - Xia,Yun-Fei, AU - Xia,Zhong-Jun, AU - Peng,Yu-Long, AU - Cai,Qing-Qing, AU - Lin,Tong-Yu, AU - Jiang,Wen-Qi, AU - Guan,Zhong-Zhen, PY - 2005/12/15/pubmed PY - 2007/9/7/medline PY - 2005/12/15/entrez SP - 1493 EP - 7 JF - Ai zheng = Aizheng = Chinese journal of cancer JO - Ai Zheng VL - 24 IS - 12 N2 - BACKGROUND & OBJECTIVE: Nasal-type NK/T-cell non-Hodgkin's lymphoma (NHL) is a unique subtype with the manifestation of local necrosis, infection and fever. The efficacy of chemotherapy alone is unsatisfactory; while radiochemotherapy plays some roles in the management of NK/T-cell lymphoma (NK/TCL). This study was to summarize the clinical characteristics, treatment outcome and prognosis of NK/TCL patients. METHODS: Records of 93 patients with NK/TCL from Jan. 1997 to Jun. 2004 were analyzed retrospectively. All the patients were classified according to WHO classification system. RESULTS: Of the 93 patients, 75 (80.6%) were in stage I-II, and 18 (19.4%) were in stage III-IV. The most common symptoms were nasal obstruction, rhinorrhea, and epistaxis. The disease course was 1-24 months with a median of 6.5 months. Of the 93 patients, 15 (16.1%) presented perforation of hard palate and/or nasal septum, 35 (37.6%) presented B symptoms; 35 (37.6%) were treated with chemotherapy alone, 2 (2.2%) were treated with radiotherapy alone, 54 (58.0%) were treated with radiochemotherapy, and 2 (2.2%) received no treatment. The first-line chemotherapy regimens were mainly CHOP and EPOCH. The overall response rate (RR) was 84.4% (76/90) with complete remission (CR) rate of 64.4% (58/90). The response rate of chemotherapy alone group was 67.6% (23/34) with CR rate of 41.2% (14/34). The response rate of combined modality group was 94.4% (51/54) with CR rate of 83.3% (45/54). The 2 patients who received no treatment died within 6 months. The major toxicity of chemotherapy was myelosuppression. The prevalence of grade III-IV neutropenia, thrombocytopenia, and anemia were 37.7%, 13.7%, and 10.7%. The major toxicities of radiotherapy were grade I-II mucosa lesion and myelosuppression. Other toxicities were mild. The mortality was 66.7% (62/93). The 1-, 3-, and 5-year overall survival (OS) rates were 63.4%, 43.1%, and 17.6%, respectively. Multivariate analysis showed that perforation of hard palate and/or nasal septum, B symptoms and therapeutic modality were independent prognostic factors of NK/TCL (P=0.035, P<0.001, and P=0.004). CONCLUSIONS: NK/TCL has low chemotherapy sensitivity. Although combined chemoradiotherapy yield better outcome, the long-term survival was still poor. Investigation of optional treatment is needed. UR - https://www.unboundmedicine.com/medline/citation/16351799/[Prognostic_analysis_of_patients_with_nasal_type_NK/T_cell_non_Hodgkin's_lymphoma__a_report_of_93_cases]_ L2 - https://medlineplus.gov/nasalcancer.html DB - PRIME DP - Unbound Medicine ER -